INB 500
Alternative Names: INB-500Latest Information Update: 23 Jan 2023
At a glance
- Originator IN8bio
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jan 2023 Preclinical trials in Cancer in USA (Parenteral) (IN8bio pipeline, January 2023)